Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 8, 2026Journal of Cardiovascular Development and DiseaseOpen Access

MRAs and SGLT2 inhibitors show potential as substrate-modifying therapies for stretch-induced arrhythmic MVP.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with arrhythmic mitral valve prolapse, defined as MVP with complex ventricular arrhythmias in the…

Design

Review

Key result

Arrhythmic mitral valve prolapse is reframed as a regional, stretch-induced cardiomyopathy, with MRAs and SGLT2 inhibitors identified as potential substrate-modifying preventive therapies.

Authors

MDMili DaveSAShaaf AhmadKAKirkwood Adams

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for substrate-directed prevention in aMVP; extends mechanistic framework but leaves open efficacy pending randomized trials.

Key Points

  • To conceptualize arrhythmic mitral valve prolapse (aMVP) as a regional stretch-induced cardiomyopathy with a fibro-inflammatory signature and identify potential substrate-modifying medical therapies.
  • Synthesized current literature across multimodal cardiac imaging, clinical electrophysiology, surgical series, mechanotransduction biology, and cardiovascular pharmacology.
  • Evaluated candidate substrate-directed drug therapies based on mechanistic plausibility, human myocardial evidence, and feasibility in randomized trials.
  • Characterized a two-hit pathogenesis whereby excessive valvular traction generates regional mechanical stress that interacts with individual susceptibility to trigger inflammation, fibrosis, and complex ventricular arrhythmias.
  • Proposed shifting the therapeutic paradigm in intermediate-risk aMVP from reactive device-based rescue toward early, substrate-directed prevention.
  • Identified mineralocorticoid receptor antagonists and sodium–glucose cotransporter 2 inhibitors as the most promising pharmacotherapies based on antifibrotic efficacy and clinical trial readiness.

Structured PICO

P
Population
Patients with arrhythmic mitral valve prolapse (aMVP), defined as MVP with complex ventricular arrhythmias in the absence of another defined arrhythmic substrate
I
Intervention
Substrate-modifying pharmacotherapies (specifically mineralocorticoid receptor antagonists [MRAs] and sodium-glucose cotransporter 2 [SGLT2] inhibitors)

This conceptual review reframes arrhythmic mitral valve prolapse as a stretch-induced cardiomyopathy and proposes MRAs and SGLT2 inhibitors as potential substrate-modifying therapies for prevention.

Cite This Study

Dave et al. (2026) conducted a review in Arrhythmic Mitral Valve Prolapse. Mineralocorticoid receptor antagonists and SGLT2 inhibitors was evaluated. Arrhythmic mitral valve prolapse is reframed as a regional, stretch-induced cardiomyopathy, with MRAs and SGLT2 inhibitors identified as potential substrate-modifying preventive therapies.

synapsesocial.com/papers/6a9fd7c658e84d0ff5b46c03https://doi.org/10.3390/jcdd13090437
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Arrhythmogenic Spectrum of Mitral Valve Disease: Pathophysiology, Risk Stratification, and Surgical Management2026
  2. 2Multimodality cardiovascular imaging in arrhythmic mitral valve prolapse: a state-of-the-art review from structural assessment to myocardial tissue characterization2026
  3. 3Progressive electrical and structural remodelling in mitral valve prolapse: implications for arrhythmic risk stratification2026
  4. 4Case Report: From multimodality imaging to catheter ablation of ventricular arrhythmias in arrhythmogenic mitral valve prolapse2025 · 1 citations
  5. 5Prevalence, clinical significance, and risk factors of arrhythmic mitral valve prolapse — results of the MITPROL AR-PL Registry2026